Nonclinical Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in the Central Nervous System

ABSTRACT Oseltamivir, a potent and selective inhibitor of influenza A and B virus neuraminidases, is a prodrug that is systemically converted into the active metabolite oseltamivir carboxylate. In light of reported neuropsychiatric events in influenza patients, including some taking oseltamivir, and as part of a full assessment to determine whether oseltamivir could contribute to, or exacerbate, such events, we undertook a series of nonclinical studies. In particular, we investigated (i) the distribution of oseltamivir and oseltamivir carboxylate in the central nervous system of rats after single intravenous doses of oseltamivir and oseltamivir carboxylate and oral doses of oseltamivir, (ii) the active transport of oseltamivir and oseltamivir carboxylate in vitro by transporters located in the blood-brain barrier, and (iii) the extent of local conversion of oseltamivir to oseltamivir carboxylate in brain fractions. In all experiments, results showed that the extent of partitioning of oseltamivir and especially oseltamivir carboxylate to the central nervous system was low. Brain-to-plasma exposure ratios were approximately 0.2 for oseltamivir and 0.01 for oseltamivir carboxylate. Apart from oseltamivir being a good substrate for the P-glycoprotein transporter, no other active transport processes were observed. The conversion of the prodrug to the active metabolite was slow and limited in human and rat brain S9 fractions. Overall, these studies indicate that the potential for oseltamivir and oseltamivir carboxylate to reach the central nervous system in high quantities is low and, together with other analyses and studies, that their involvement in neuropsychiatric events in influenza patients is unlikely.

[1]  W. Löscher,et al.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family , 2011, NeuroRX.

[2]  T. Weiser,et al.  Oseltamivir is Devoid of Specific Behavioral and Other Central Nervous System Effects in Juvenile Rats at Supratherapeutic Oral Doses , 2009 .

[3]  H. Kusuhara,et al.  Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Res , 2009, Drug Metabolism and Disposition.

[4]  N. J. White,et al.  Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.

[5]  L. Ereshefsky,et al.  Low Penetration of Oseltamivir and Its Carboxylate into Cerebrospinal Fluid in Healthy Japanese and Caucasian Volunteers , 2008, Antimicrobial Agents and Chemotherapy.

[6]  R. Webster,et al.  Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. , 2008, The Journal of infectious diseases.

[7]  H. Kusuhara,et al.  P-glycoprotein Restricts the Penetration of Oseltamivir Across the Blood-Brain Barrier , 2008, Drug Metabolism and Disposition.

[8]  F. Hayden,et al.  Update on avian influenza A (H5N1) virus infection in humans. , 2008, The New England journal of medicine.

[9]  T. Fujita,et al.  Oseltamivir (Tamiflu) Efflux Transport at the Blood-Brain Barrier via P-Glycoprotein , 2008, Drug Metabolism and Disposition.

[10]  R. Gieschke,et al.  Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir , 2008, Drug safety.

[11]  W. A. Blumentals,et al.  The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. , 2007, MedGenMed : Medscape general medicine.

[12]  K. Tanimoto,et al.  Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro , 2007, Pharmacogenetics & Genomics.

[13]  F. Hayden.  Writing Committee of the Second World Health Organization (WHO) Consultation on Clinical Aspects of Human Infection with Avian Influenza A(H5N1) Virus , 2007 .

[14]  R. Myerburg,et al.  Whole blood RNA offers a rapid, comprehensive approach to genetic diagnosis of cardiovascular diseases , 2007, Genetics in Medicine.

[15]  F. Akhlaghi,et al.  Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel , 2006, Journal of Pharmacology and Experimental Therapeutics.

[16]  M. Yılmaz,et al.  Anthrax meningoencephalitis secondary to oral infection. , 2006, The Pediatric infectious disease journal.

[17]  A. Okumura,et al.  Oseltamivir and delirious behavior in children with influenza. , 2006, The Pediatric infectious disease journal.

[18]  Teruko Imai,et al.  Human carboxylesterase isozymes: catalytic properties and rational drug design. , 2006, Drug metabolism and pharmacokinetics.

[19]  E. Duysen,et al.  Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. , 2005, Biochemical pharmacology.

[20]  J. Oxford.  Oseltamivir in the management of influenza , 2005, Expert opinion on pharmacotherapy.

[21]  A. Moscona.  Neuraminidase inhibitors for influenza. , 2005, The New England journal of medicine.

[22]  T. Abe,et al.  Involvement of Multiple Transporters in the Efflux of 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors across the Blood-Brain Barrier , 2004, Journal of Pharmacology and Experimental Therapeutics.

[23]  J. Robert,et al.  Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN‐38 , 2004, Clinical pharmacology and therapeutics.

[24]  M. Kurowski,et al.  Oseltamivir Distributes to Influenza Virus Replication Sites in the Middle Ear and Sinuses , 2004, Clinical drug investigation.

[25]  H. Kusuhara,et al.  Contribution of Organic Anion Transporter 3 (Slc22a8) to the Elimination of p-Aminohippuric Acid and Benzylpenicillin across the Blood-Brain Barrier , 2003, Journal of Pharmacology and Experimental Therapeutics.

[26]  Jörg Huwyler,et al.  Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. , 2003, Journal of medicinal chemistry.

[27]  B. Yan,et al.  Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[28]  P. Ward,et al.  The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[29]  R. Webster,et al.  Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses , 2001, Antimicrobial Agents and Chemotherapy.

[30]  R. Webster,et al.  The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. , 2000, Antiviral research.

[31]  D. Beier,et al.  Developmentally regulated expression of organic ion transporters NKT (OAT1), OCT1, NLT (OAT2), and Roct. , 2000, American journal of physiology. Renal physiology.

[32]  P. Ward,et al.  Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802 , 1999, Clinical pharmacokinetics.

[33]  K. Chiba,et al.  cDNA cloning, characterization and stable expression of novel human brain carboxylesterase , 1999, FEBS letters.

[34]  F. Soriano,et al.  In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens. , 1998, The Journal of antimicrobial chemotherapy.

[35]  Norbert Bischofberger,et al.  Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 , 1998, Antimicrobial Agents and Chemotherapy.